Speaker Profile
MS, MBA, PMP, VP, Team Leadership and Precision Medicine, Ignyta
Biography
Eric leads two targeted oncology drug candidates in clinical development where the teams combine Ignyta’s precision therapeutics (Rx) and molecular diagnostics (Dx) to identify and target hard-to-treat cancers in hard-to-find patients. Eric has worked in oncology drug development for the last 16 years on 23 clinical compounds (small molecules, mAbs, vaccines) across all phases of development (preclinical through phase IV) including a leadership role in the development of palbociclib for ER+ breast cancer. As an active member of BIOCOM and Cancer Moonshot subteams, Eric’s external focus is helping to drive efficiencies in precision medicine. Prior to developing oncology drugs, Eric served in the military for 22 yrs before retiring as a Commander.
Talk
An Innovative Approach For Dx-Driven Oncology Trials
Enrolling biomarker-driven patient populations harboring rare molecular alterations in a global basket trial to support registration is a key challenge to sponsors. Employing a globally integrated precision therapeutic and companion diagnostic strategy is a solution to finding, enrolling and successfully treating rare patient populations. Patient case studies are discussed.
